MedTrace Logo

The Chimerix CMX001 Registry

NCT02167685 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 550

Last updated 2019-05-17

No results posted yet for this study

Summary

The prospective observational study is to establish a registry database to evaluate the potential impact of prior treatment with CMX001 on the long-term incidence of specific events, such as outcomes, late CMV and other Double-stranded DNA virus associated events, s well as survival rates in subjects previously enrolled in selected clinical studies of CMX001. Each Registry participant will be followed for a period of approximately 3 years from their enrollment in the Registry.

Conditions

  • Outcomes
  • Survival Rates

Interventions

DRUG

CMX001

Sponsors & Collaborators

Eligibility

Min Age
6 Months
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2019-05-10
Completion
2019-05-10

Countries

  • United States
  • Belgium
  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02167685 on ClinicalTrials.gov